ProShares UltraShort Nasdaq Biotechnology (PS6G)
XBER 
NASDAQ (NMS) Primary XBER Summary
PS6G Chart
BIS says debt, AI boom and fragilities raise global risks
Global pressures from rising public debt to financial fragilities and the sustainability of the AI boom are increasing risks, underscoring the need for disciplined policymaking, according to the Bank for International Settlements.
BIS says gold and equities are in bubble territory
Neils Christensen has a diploma in journalism from Lethbridge College and has more than a decade of reporting experience working for news organizations throughout Canada. His experiences include covering territorial and federal politics in Nunavut, Canada.
Top Performing Leveraged/Inverse ETFs: 05/11/2025
Top Performing Leveraged/Inverse ETFs Last Week These were last week's top performing leveraged and inverse ETFs. Note that because of leverage, these kinds of funds can move quickly.
ProShares UltraShort Nasdaq Biotechnology (PS6G) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has ProShares UltraShort Nasdaq Biotechnology ever had a stock split?
ProShares UltraShort Nasdaq Biotechnology Profile
| XBER Exchange | US Country |
Overview
The company presented offers a financial fund that focuses on investing in the biotechnology and pharmaceutical sectors, specifically targeting companies listed on the Nasdaq. By using financial instruments, ProShare Advisors aims to achieve daily returns that align with a predetermined Daily Target. This objective is pursued through a strategic selection of securities that form part of a modified capitalization weighted index, encapsulating the dynamism and potential of the biotech and pharmaceutical industries. Unlike many investment funds, this fund is not diversified, concentrating its investments in a specialized sector to capitalize on specific market opportunities.
Products and Services
- Daily Return Investment Strategy
This product is designed for investors seeking daily investment results that correspond to the fund's Daily Target. By employing a variety of financial instruments, the fund aims to match or outperform its defined objective on a daily basis, offering a proactive approach to investment in the biotechnology and pharmaceutical sectors. This strategy caters to those with a keen interest in the volatility and growth potential inherent in these industries.
- Modified Capitalization Weighted Index
The fund's approach to investment is grounded in a modified capitalization weighted index, incorporating Nasdaq-listed biotechnology and pharmaceutical companies. This methodology ensures a balanced yet growth-focused portfolio, aiming to reflect the performance and potential of leading and emerging companies within these innovative sectors. It’s a strategic choice for investors looking to benefit from the specific market movements of the biotech and pharmaceutical industries.
- Non-Diversified Portfolio
As a non-diversified fund, this product offers a concentrated investment in the biotechnology and pharmaceutical sectors without the dilution of focus associated with broader diversified portfolios. This approach is particularly suitable for investors who wish to deeply engage with these specific sectors, leveraging the higher risk and potential reward scenario that such focused investment strategies can offer.
